Pathology of Urinary Bladder Inverted Papilloma
No Results
No Results
processing….
A rare yet benign neoplasm, the inverted papilloma is an endophytic urothelial tumor of moderate significance due to its variable similarity to inverted urothelial carcinoma, which holds a much more aggressive prognosis. The term inverted papilloma was first introduced by Potts & Hirst in 1963, [1] although originally Paschkis described the entity in the bladder in 1927, [2] calling it a polypoid adenoma. The term Brunnian adenoma has also been used, as the lesion bears a modest resemblance to normal Brunn’s nests.
The key histologic criteria that separate this benign lesion from its malignant counterpart center on cytologic atypia, which is absent to minimal in inverted papillomas but invariably present in urothelial carcinoma. Although morphologic overlap does exist between the 2 entities, the inverted papilloma has a favorable prognosis, with little if any malignant potential.
Inverted papillomas are infrequent and account for less than 1% of urothelial neoplasms. [3, 4] They occur predominantly in men, with a male-to-female ratio of 4-7:1, typically in the 5th to 6th decade of life, although the incidence can range from early adolescence to the mid-90s. [3, 5] Most inverted papillomas are discovered incidentally during routine urologic investigations for bladder outlet obstruction, hematuria, or flank pain. Occasionally inverted papillomas are discovered on follow-up examinations for urothelial malignancies, which in part lends to the discussion regarding their malignant association. [6]
Although the prevalence of urothelial tumors is higher among smokers, this correlation is predominately seen with p53 gene mutations, and consequently, they are associated with higher-grade malignancies. [7, 8] Inverted papillomas have not been shown to harbor p53 gene mutations, though they have been shown to occasionally possess over accumulation of p53 gene products, with one study finding such accumulations in 18.9% of inverted papillomas examined. [4, 9, 10] It should be stressed, thus, that p53 mutations are inherently associated with malignancy but are not intrinsically related to inverted papillomas.
Inverted papillomas arise in the setting of molecular changes that are not fully understood but are genetically distinct from the alterations seen in urothelial carcinoma. [11] Rare cases have been documented regarding malignant transformation of inverted papillomas, but it is unclear whether such cases represent a true transformation, a misclassification of urothelial carcinoma, or inverted papilloma arising in the setting of urothelial carcinoma (and vice versa). [12, 13]
The fibroblast growth factor receptor (FGFR3) gene has been implicated in low-grade urothelial malignancies, and consequently some evidence points toward the involvement of FGFR3 mutations in inverted papillomas, although the evidence is variable and ranges from 9.8% in one study of 62 inverted papillomas [14] to 45% in a study of 20 inverted papillomas. [9]
Alexander et al investigate the suggestion that human papillomavirus (HPV) plays an etiologic role in the development of inverted papilloma of the urinary bladder by evaluating 27 inverted papillomas of the urinary bladder for the presence of HPV. Both immunohistochemical and in situ hybridization (ISH) studies for HPV and immunohistochemical analysis for p16, a surrogate marker for HPV infection, were used to assess HPV infection status. The authors’ findings indicate the absence of HPV in urothelial inverted papillomas and as a result concluded that HPV testing should not be used as a diagnostic adjunct for inverted papilloma cases. [15]
The majority (70%) of inverted papillomas occur in the bladder, most often in the trigone, followed by the bladder neck, bladder dome, posterior wall, and lateral wall. The remaining 30% of inverted papillomas occur in the ureter, renal pelvis, and urethra in decreasing frequency. [3]
The most common symptoms of inverted papillomas, leading to their discovery, are bladder outlet obstruction, hematuria, dysuria, and irritative voiding, with approximately 25% of cases presenting with more than one symptom. Less common symptoms are suprapubic pain and pyuria.
Grossly, inverted papillomas are a pedunculated polypoid lesion or a sessile lesion with a smooth surface, covered with grossly normal-appearing urothelial epithelium, and they are usually located in the trigone. Inverted papillomas range in size from a few millimeters to 3 to 4 centimeters in greatest dimension.
The overall pattern of inverted papillomas is that of cords and trabeculae of urothelial cells that grow into the underlying lamina propria but not the muscularis propria, producing a localized, noninvasive endophytic mass covered by histologically and cytologically normal urothelium. The cords and trabeculae generally contain normal urothelial cells centrally, with darkened, palisading basal cells at the periphery. Rare atypical cells can be found, but these are more of the exception than the rule. Conversely, the more aggressive urothelial carcinoma generally has a thicker, irregularly shaped pattern of cords with transitioning into solid areas, cytologic atypia, nuclear pleomorphism with irregular chromatin distribution, and prominent nucleoli. The general order and peripheral palisading are usually absent in urothelial carcinoma. See the images below.
Debate arises in the literature pertaining to different subclasses of inverted papillomas, specifically, trabecular and glandular variants; however evidence suggests the glandular subtype is histologically indistinguishable from another urothelial entity, cystitis cystica or glandular cystitis. Other variations, however, are occasionally recognized, including basaloid, hyperplastic, and spindle cell / medullary, in addition to nonkeratinizing or neuroendocrine differentiation.
Classic inverted papillomas rarely express the immunohistologic markers of the more worrisome urothelial carcinoma, which include p53, Ki-67, and cytokeratin 20. Whereas inverted papillomas with atypia have been found to occasionally harbor some positivity for p53 and Ki-67, typical inverted papillomas show no immunohistochemical positivity. Scant positivity to immunohistochemical markers should be interpreted in conjunction with cellular features, overall architecture and, if necessary, fluorescence in situ hybridization (FISH) analysis.
High-grade urothelial malignancies often harbor mutations of the p53 gene, a tumor suppressor gene known to be influenced by smoking, whereas inverted papillomas have not been shown to consistently exhibit such mutations. Evidence does exist, albeit of variable nature, that inverted papillomas do occasionally possess mutations in the FGFR3 gene, which normally produces a receptor known as the fibroblast growth factor receptor and which is involved in cell signaling. [7, 16]
Very few tumors have been identified that harbor both p53 and FGFR3 mutations, and it has not been definitively answered whether this equates to alternate tumorigenesis pathways or inverted papillomas as a precursor lesion. Supporting separate tumorigenesis are recent developments in molecular testing using FISH assays to detect abnormalities in chromosomes 3, 7, 17, and 21. Such anomalies have been detected in urothelial carcinoma but not in inverted papillomas, supporting the alternate pathogenesis hypothesis. Similar mutations have been identified in loss of heterozygosity (LOH) studies, which consistently exhibit changes found in urothelial carcinoma but not in inverted papilloma.
The standard treatment for inverted papilloma of the lower urinary tract is transurethral resection (TUR), whereas cases involving the upper urinary tract require various degrees of surgical resection depending on the level of certainty of the behavior of the tumor and whether there is concurrent urothelial carcinoma. The benignity of the lesion precludes any staging.
The prognosis for inverted papilloma is quite good, with a recurrence rate of less than 5%, and the likelihood of synchronous or subsequent development of urothelial carcinoma 6% and 3%, respectively.
The main consideration in the differential diagnosis is urothelial carcinoma with inverted pattern. Distinction between the two entities can sometimes be difficult histologically due to specimen size, crush and thermal artifact, and general histologic features which overlap, although the amount of cytologic atypia, morphologic and architectural patterns, and mitotic count should be helpful in pointing to a benign or malignant diagnosis.
In cases of difficult histologic discernment, immunohistochemistry can be of assistance, as urothelial carcinoma has positivity for Ki-67, p53, and cytokeratin 20, whereas inverted papillomas generally do not express these markers. Additionally, FISH analysis is capable of detecting chromosomal anomalies that are often present in urothelial carcinoma but absent in inverted papilloma.
Additional considerations include aggregates of von Brunn’s nests (distinct nests of solid urothelium within the lamina propria) and inverted papillary urothelial neoplasms of low malignant potential (PUNLMP; similar to von Brunn’s nests but with prominent branching). Another entity to keep in mind, particularly in younger patients, is fibroepithelial polyps. Fibroepithelial polyps can present in a manner clinically similar to inverted papillomas and may have a histologically similar appearance, although architecturally fibroepithelial polyps are — by nature — exophytic or pedunculated, and display a more dense stroma with fibrovascular cores.
Potts IF, Hirst E. Inverted papilloma of the bladder. J Urol. 1963 Aug. 90:175-9. [Medline].
Paschkis R. Uber adenoma der harnblase. Z Urol Chir. 1927. 21:315-25.
Sung MT, Maclennan GT, Lopez-Beltran A, Montironi R, Cheng L. Natural history of urothelial inverted papilloma. Cancer. 2006 Dec 1. 107(11):2622-7. [Medline]. [Full Text].
Sung MT, Eble JN, Wang M, Tan PH, Lopez-Beltran A, Cheng L. Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol. 2006 Oct. 19(10):1289-94. [Medline].
Kunze E, Schauer A, Schmitt M. Histology and histogenesis of two different types of inverted urothelial papillomas. Cancer. 1983 Jan 15. 51(2):348-58. [Medline].
Brown AL, Cohen RJ. Inverted papilloma of the urinary tract. BJU Int. 2011 Apr. 107 Suppl 3:24-6. [Medline].
van Rhijn BW, van der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004 Mar 15. 64(6):1911-4. [Medline]. [Full Text].
van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol. 2002 Oct. 198(2):245-51. [Medline].
Lott S, Wang M, Zhang S, et al. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Mod Pathol. 2009 May. 22(5):627-32. [Medline].
Amin MB, Gomez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol. 1997 Sep. 21(9):1057-68. [Medline].
Hodges KB, Lopez-Beltran A, Maclennan GT, Montironi R, Cheng L. Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management. BJU Int. 2011 Feb. 107(4):532-7. [Medline].
Altaffer LF 3rd, Wilkerson SY, Jordan GH, Lynch DF. Malignant inverted papilloma and carcinoma in situ of the bladder. J Urol. 1982 Oct. 128(4):816-8. [Medline].
Renfer LG, Kelley J, Belville WD. Inverted papilloma of the urinary tract: histogenesis, recurrence and associated malignancy. J Urol. 1988 Oct. 140(4):832-4. [Medline].
Eiber M, van Oers JM, Zwarthoff EC, et al. Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol. 2007 Jun. 31(6):938-46. [Medline].
Alexander RE, Davidson DD, Lopez-Beltran A, Montironi R, MacLennan GT, Compérat E, et al. Human papillomavirus is not an etiologic agent of urothelial inverted papillomas. Am J Surg Pathol. 2013 Aug. 37(8):1223-8. [Medline].
van Oers JM, Lurkin I, van Exsel AJ, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005 Nov 1. 11(21):7743-8. [Medline]. [Full Text].
Asano K, Miki J, Maeda S, Naruoka T, Takahashi H, Oishi Y. Clinical studies on inverted papilloma of the urinary tract: report of 48 cases and review of the literature. J Urol. 2003 Oct. 170(4 Pt 1):1209-12. [Medline].
Broussard JN, Tan PH, Epstein JI. Atypia in inverted urothelial papillomas: pathology and prognostic significance. Hum Pathol. 2004 Dec. 35(12):1499-504. [Medline].
Caro DJ, Tessler A. Inverted papilloma of the bladder: a distinct urological lesion. Cancer. 1978 Aug. 42(2):708-13. [Medline].
Cheon J, Kim HK, Kim JJ, Yoon DK, Koh SK, Kim IS. Malignant inverted papilloma of the urinary bladder: the histopathological aspect of malignant potential of inverted papilloma. J Korean Med Sci. 1995 Apr. 10(2):103-10. [Medline]. [Full Text].
Fine SW, Chan TY, Epstein JI. Inverted papillomas of the prostatic urethra. Am J Surg Pathol. 2006 Aug. 30(8):975-9. [Medline].
Grainger R, Gikas PW, Grossman HB. Urothelial carcinoma occurring within an inverted papilloma of the ureter. J Urol. 1990 Apr. 143(4):802-4. [Medline].
Ho H, Chen YD, Tan PH, Wang M, Lau WK, Cheng C. Inverted papilloma of urinary bladder: is long-term cystoscopic surveillance needed? A single center’s experience. Urology. 2006 Aug. 68(2):333-6. [Medline].
Jones TD, Zhang S, Lopez-Beltran A, et al. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol. 2007 Dec. 31(12):1861-7. [Medline].
Kyriakos M, Royce RK. Multiple simultaneous inverted papillomas of the upper urinary tract. A case report with a review of ureteral and renal pelvic inverted papillomas. Cancer. 1989 Jan 15. 63(2):368-80. [Medline].
Mattelaer J, Leonard A, Goddeeris P, D’Hoedt M, Van Kerrebroeck P. Inverted papilloma of bladder: clinical significance. Urology. 1988 Sep. 32(3):192-7. [Medline].
Tsuzuki T, Epstein JI. Fibroepithelial polyp of the lower urinary tract in adults. Am J Surg Pathol. 2005 Apr. 29(4):460-6. [Medline].
Joseph Eaton, DO Resident Physician, Department of Pathology, Indiana University School of Medicine
Joseph Eaton, DO is a member of the following medical societies: American Medical Association, American Society for Clinical Pathology, College of American Pathologists
Disclosure: Nothing to disclose.
Antonio Lopez-Beltran, MD, PhD Professor of Anatomic Pathology, Unit of Anatomic Pathology, Department of Surgery, Cordoba University School of Medicine, Spain
Disclosure: Nothing to disclose.
Rodolfo Montironi, MD, FRCPath, FCAP Professor of Pathology, Institute of Pathological Anatomy, Polytechnic University of the Marche Region, United Hospitals, Italy; Associate Investigator, University of Arizona College of Medicine
Rodolfo Montironi, MD, FRCPath, FCAP is a member of the following medical societies: College of American Pathologists, European Society of Pathology, International Society of Urological Pathology, Royal College of Pathologists
Disclosure: Nothing to disclose.
Liang Cheng, MD Professor of Pathology and Urology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine; Chief, Genitourinary Pathology Service, Indiana University Health
Liang Cheng, MD is a member of the following medical societies: American Association for Cancer Research, American Urological Association, College of American Pathologists, United States and Canadian Academy of Pathology, International Society of Urological Pathology, Arthur Purdy Stout Society
Disclosure: Nothing to disclose.
Liang Cheng, MD Professor of Pathology and Urology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine; Chief, Genitourinary Pathology Service, Indiana University Health
Liang Cheng, MD is a member of the following medical societies: American Association for Cancer Research, American Urological Association, College of American Pathologists, United States and Canadian Academy of Pathology, International Society of Urological Pathology, Arthur Purdy Stout Society
Disclosure: Nothing to disclose.
Pathology of Urinary Bladder Inverted Papilloma
Research & References of Pathology of Urinary Bladder Inverted Papilloma |A&C Accounting And Tax Services
Source
0 Comments